Euronext-listed Onward Medical, a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries, has €40.6m by way of an accelerated bookbuild offering through a private placement with institutional investors.
Some 13,520,254 new ordinary shares were issued at €3.00 per share, which brings the company’s share capital to 69,528,780 shares.
EQT Life Sciences invested €25m.
“The strong support from EQT and other high-quality investors underscores the rapid adoption of the ARC-EX System and validates our successful transition to a commercial-stage organisation,” said Dave Marver, CEO.
The ARC-EX System is intended to be operated in medical centres by rehabilitation professionals and at home by patients and persons providing assistance to patients.
Proceeds from will fund development, expand commercial operations, general corporate purposes and service existing debt.
In October 2025, Onward raised €50.85m through a private placement, with Ottobock as cornerstone investor.
Stifel Europe Securities was sole global coordinator and joint books. Bank Degroof Petercam was joint books.
